Really, you read \u201cThe Hill\u201d<\/a> article, you literally don\u2019t know anything.<\/p>\n According to a former federal trade official, enforcing this sort of directive will not be simple, especially the provision requiring facility development in the U.S.<\/p>\n \u201cHow on earth do you enforce that? How do you make sure that that is clear at the time of import? Even more so, [Harmonized Tariff Schedule] codes don\u2019t distinguish between brand and generi<\/strong>c,\u201d Monica Gorman, managing director at Crowell Global Advisors and former special assistant to former\u00a0President Biden\u00a0<\/a><\/span>for manufacturing & industrial policy, told The Hill.<\/p>\n \u201cEnforcing this is going to be incredibly challenging, but at least from an immediate impact standpoint, the fact that it appears to exclude generics is incredibly important and is likely to lessen the impact on the American patients,\u201d she added.<\/p>\n It remains unclear whether this order was informed by the Section 232 investigation ordered by the Trump administration.<\/p>\n Earlier this year, the Commerce Department initiated an\u00a0investigation<\/a>\u00a0into the national security impact of importing pharmaceuticals and pharmaceutical ingredients. This was done under the Section 232 of the Trade Expansion Act of 1962, which gives the president authority to restrict imports that may threaten national security.<\/p>\n If this action was spurred by the 232 investigation, then the tariffs may be stronger as a result.<\/p>\n \u2026<\/p>\n [emphasis added]<\/strong><\/p>\n<\/blockquote>\n Open question: Don\u2019t we need a report released before Section 232 tariffs are imposed?<\/p>\n\n
![\"\"](\"https:\/\/econbrowser.com\/wp-content\/uploads\/2025\/09\/eputradetpud14.png\")
<\/a><\/p>\n